Sursum schreef op 10 oktober 2018 08:43:
Undervaluing Pharming Group NV (AMS:PHARM) By 36.18%
in.finance.yahoo.com/news/investors-u...DCF calculation shouldn’t be the only metric you look at when researching a company. What is the reason for the share price to differ from the intrinsic value? For PHARM, I’ve compiled three fundamental aspects you should further research:
1.Financial Health:
Does PHARM have a healthy balance sheet? 2.Future Earnings: How does PHARM’s growth rate compare to its peers and the wider market?
3.Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of PHARM?